Centene is in a powerful, sustained uptrend: the stock is up 104.22% over the past year and 67.95% year-to-date, and at $70.17 it sits at roughly 94.7% of its 52-week range of $31.63 to $72.50, just 3.2% below the high. That positioning signals strong momentum leadership rather than a value entry point — the stock has already re-rated dramatically off its lows, and the 91.09-point relative strength versus SPY over one year confirms it has massively outperformed the market. The risk embedded in trading near the top of the range is overextension and vulnerability to profit-taking, particularly given a max drawdown of -32.73% over the trailing period, which shows this name can de-rate violently when sentiment shifts.

Short-term momentum is accelerating and confirms the longer-term trend rather than diverging from it: the stock is up 13.03% over the past month and 10.66% over three months, with the one-month gain far outpacing the 2.85% three-month SPY return and producing a 14.05-point one-month relative strength spread. The most recent sequence is particularly constructive — the stock climbed from $60.99 on October 1 to $71.24 on October 22, a roughly 16.8% move in under four weeks, before a modest 1.50% pullback to $70.17 on the latest session on volume of about 4.31 million shares. Momentum accelerating into new highs after a 67.79% six-month run suggests trend persistence, but the vertical slope of the October advance raises the odds of a short-term consolidation; a short ratio of 2.15 indicates bears are not aggressively positioned, removing a potential squeeze catalyst but also limiting forced-covering fuel.

Key technical levels are well defined: immediate resistance is the 52-week high at $72.50, roughly 3.3% above the current $70.17, and a decisive breakout above that level would confirm the uptrend and likely invite momentum and trend-following capital, opening blue-sky territory. Support sits at the $60.99-$62.00 shelf established in late September and early October, with the 52-week low of $31.63 as the ultimate floor — a breakdown below the $61 area would signal a failed breakout and probable mean reversion toward the mid-$50s. With a beta of 1.13, the stock is about 13% more volatile than the market, meaning position sizing should account for amplified drawdowns in risk-off tape; combined with the -32.73% max drawdown, this argues for disciplined stop placement rather than passive holding at current extended levels.

The revenue trajectory is contracting at the top line even as profitability inflects: Q2 2026 revenue was $44.375 billion, down 8.96% year-over-year from $48.742 billion in Q2 2025, following Q1 2026 revenue of $49.944 billion versus $46.620 billion a year earlier — a pattern of sequential decline from Q1 to Q2 that reflects ACA membership attrition and Medicaid redeterminations. Segment data shows the concentration clearly: Medicaid at $31.97 billion, Medicare at $11.057 billion, Commercial at $9.356 billion, and Other at $1.196 billion, meaning the Medicaid book is roughly 59% of the disclosed segment total and the exchange-linked Commercial book is the swing factor being pressured by membership losses. The investment case therefore hinges not on growth but on whether cost discipline and rate adequacy can lift margins faster than membership declines erode the revenue base — a classic managed-care margin-over-mix trade-off.

Profitability has swung decisively positive after a disastrous 2025: Q2 2026 net income was $1.091 billion (EPS $2.21 diluted, $2.19) versus a net loss of $253 million in Q2 2025, and Q1 2026 net income was $1.541 billion (EPS $3.13) versus $1.311 billion a year prior. The reported Q2 gross margin of 10.4% ($4.617 billion gross profit on $44.375 billion revenue) is thin in absolute terms but normal for a health insurer whose "cost of revenue" is medical claims; the operating margin of 3.10% and net margin of 2.46% in Q2 compare with a deeply negative Q3 2025 operating margin of -13.99% and net margin of -13.34%, illustrating the magnitude of the swing. The key caveat is quality of earnings: the trailing-twelve-month net margin of -3.43% and negative trailing EPS of -$0.33 still reflect the 2025 losses, and the Q1 2026 gross margin of 21.9% versus Q2's 10.4% shows significant quarter-to-quarter volatility in claims and reserve development, so investors should treat the recent margin expansion as partly cyclical recovery rather than a fully proven structural improvement.

Balance sheet and cash generation are the strongest part of the story: Q2 2026 operating cash flow was $4.373 billion with free cash flow of $4.199 billion (capex of only $174 million), and TTM free cash flow is $8.968 billion against a market cap of roughly $20.2-$30.7 billion — an extraordinarily high FCF yield that reflects the insurer's negative working-capital-funded cash model. Cash at period end was $24.254 billion, the current ratio is 1.68, and debt-to-equity is 0.94, with Q2 debt repayment of $258 million and Q1 repayment of $1.046 billion showing active deleveraging. The offset is a negative ROE of -33.44% on a trailing basis (a legacy of 2025 losses) and a low ROA of 2.48%, so while liquidity and cash conversion are excellent, returns on capital remain depressed and the equity base is still recovering — the company funds itself internally with ease, but book-value-based returns will take several clean quarters to normalize.